Emerging Technologies: Stem cells

Emerging Technologies: Stem cells - Stem cell therapies will play an increasingly important role in the underserved field of regenerative medicine, as preclinical discoveries are translated into the clinical setting and product candidates slowly progress through a diverse pipeline.

Features and benefits
• A full stem cell pipeline by each therapeutic category from preclinical stage to registration candidates.
• Provides an insight into key players, recent deals and developments.

Browse All: Biotechnology Market Research Reports 

Highlights
Small and medium-sized research-led companies dominate the stem cells landscape, with a few large pharmaceutical companies beginning to invest in recent years. This sector is highly heterogeneous, consisting of different stem cells technology platforms, including embryonic and adult stem cells, applied in a wide range of therapy areas.

Geron’s recent divestment in the sector highlights the several technical challenges associated with the application of stem cells in certain therapy areas, in particular, the central nervous system.

Table Of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Introduction to stem cells
Stem cell pipeline
Key players
Data sourcing

EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Recent updates

INTRODUCTION TO STEM CELLS
Key findings
An introduction to stem cells
Types of stem cells
Pipeline snapshotAlthough bone marrow stem cell transplant has been routinely used for over 4 decades to treat hematological malignancies, the potential of stem cells to regenerate or replace highly specialized damaged or lost tissues in serious degenerative disorders or debilitating diseases, such as myocardial infarction, spinal cord injuries, ischemic stroke, macular degeneration, diabetes, and multiple sclerosis, has yet to be realized. Key limitations that still need to be addressed include successful delivery, differentiation, engraftment, integration, vascularization, functionality, and long-term safety of the transplanted cells. In view of this, several companies are currently exploiting more easily achievable goals, using a more drug-like approach that utilizes stem cells to alter physiological conditions within the damaged tissue and that indirectly promotes repair and regulates inflammatory and immunomodulatory pathways.
SWOT analysis
Strengths
Opportunities
Weaknesses
Threats

STEM CELL PIPELINE
Key findings
Stem cell pipeline overview
Cardiovascular
Central nervous system
Ophthalmology
Endocrine and metabolic disorders
Immunology and inflammation
Musculoskeletal
Other indications

THE KEY PLAYERS
Overview
Mesoblast
Osiris Therapeutics
Athersys
Gamida Cell
Cytori Therapeutics
Geron

APPENDIX
References
Datamonitor research
Journal papers
Exchange rates